Angiogenic Factor-Based Signature Predicts Prognosis and Immunotherapy Response in Non-Small-Cell Lung Cancer
Article in Frontiers in Genetics (May 2022)
The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.
TRIM46 activates AKT/HK2 signaling by modifying PHLPP2 ubiquitylation to promote glycolysis and chemoresistance of lung cancer cells
Article in Cell Death & Disease (March 2022)
Angiogenic Factor-Based Signature Predicts Prognosis and Immunotherapy Response in Non-Small-Cell Lung Cancer
Preprint in Research Square (March 2022)